# US 2024/0252471 A1 · Non-sedating dexmedetomidine treatment regimens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0252471 A1
- Document ID: US20240252471A1
- Status: Published application
- Kind: A1
- Application number: 18/526,686
- Filed: 2023-12-01
- Published: 2024-08-01
- Earliest claimed: 2023-01-12
- Assignees: BioXcel Therapeutics, Inc.
- Applicants: BioXcel Therapeutics, Inc.
- Inventors: Vasukumar KAKUMANU; David Christian HANLEY; Frank YOCCA; Chetan Dalpatbhai LATHIA; Lavanya RAJACHANDRAN; Robert RISINGER
- Web page: https://patentgrep.com/patent/US20240252471A1

## CPC

- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

## Claims

### Claim 1

A method of treating agitation associated with schizophrenia or bipolar I or II disorder in a human subject comprising:
administering a first dose of dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation to the human subject;
wherein the human subject has a severe hepatic impairment and the agitation is mild or moderate; and
wherein the first dose is 60 mcg of dexmedetomidine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agitation is severe as defined by a PEC score of 20 or higher and the hepatic impairment is severe (Child-Pugh Class C).

### Claim 3 (depends on 1)

The method of claim 1, wherein the oromucosal formulation further comprises at least one water-soluble polymer.

### Claim 4 (depends on 3)

The method of claim 3, wherein the at least one water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl cellulose, carboxy methylcellulose, methylcellulose, polyethylene oxide (PEO), and mixtures thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein the at least one water-soluble polymer is hydroxypropyl cellulose.

### Claim 6 (depends on 1)

The method of claim 1, wherein a second dose of dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation is administered to the human subject at least two hours after and within 24 hours of the first dose and wherein the second dose is 60 mcg of dexmedetomidine.

### Claim 7 (depends on 6)

The method of claim 6, wherein a third dose of dexmedetomidine or a pharmaceutically acceptable salt thereof in an oromucosal formulation is administered to the human subject at least two hours after the second dose and within 24 hours of the first dose and wherein the third dose is 60 mcg of dexmedetomidine.
